Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693292 | 1.00 | PTGS2 (0.48) | PTGS2PTGS1LMNAHPGDTDP1 | |
| SCHEMBL1960131 | 0.83 | LMNA (0.45) | PTGS2PTGS1LMNAHPGDTDP1 | |
| SCHEMBL5723333 | 0.80 | LMNA (0.45) | PTGS2PTGS1LMNAHPGDTDP1 | |
| SCHEMBL20101689 | 0.79 | LMNA (0.52) | PTGS2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL31717974 | 0.79 | KMT2A (0.50) | PTGS2LMNATDP1ALDH1A1KMT2A | |
| SCHEMBL6139521 | 0.79 | PTGS2 (0.69) | PTGS2PTGS1LMNAHPGDERN1 | |
| SCHEMBL14070022 | 0.77 | LMNA (0.64) | LMNAHPGDTDP1ALDH1A1KMT2A | |
| SCHEMBL19153574 | 0.75 | PTPRC (0.56) | PTGS2PTGS1LMNAHPGDTDP1 | |
| SCHEMBL12722842 | 0.73 | PTGS2 (0.48) | PTGS2PTGS1HPGDALDH1A1CYP1A2 | |
| SCHEMBL1664233 | 0.72 | TP53 (0.48) | PTGS2PTGS1ALDH1A1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773354-B | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2023-03-24 | — | — | CN | claimed |
| CN-114773354-A | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2022-07-22 | — | — | CN | claimed |
| CN-116003320-A | Preparation method of phenanthridine compound | 武汉理工大学深圳研究院 | 2023-04-25 | — | — | CN | disclosed |
| CN-114773354-B | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114773354-B | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-114773354-A | Simple synthesis method of Trisphaeridine | 武汉理工大学 | 2022-07-22 | — | — | CN | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | GPER1, ESR2, ESRRG | PTGS2 1198/4885PTGS1 655/4885LMNA 2955/4885 |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | GPER1, ESR2, ESRRG | PTGS2 1322/4885PTGS1 766/4885LMNA 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.